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Spectacled cobra in a rice field 
in West Bengal: W Wüster 
CAN WE SOLVE THE SNAKEBITE CRISIS IN INDIA? 
India has the capacity and skills to solve the problem but it will require political will, co-
ordinated action and a well-funded programme which encourages co-operation between 











SnakSymp, an annual symposium of the Toxinology society of India (TSI), attracts diverse interest groups 
including medical doctors, scientists working on aspects of snake biology, venom proteins and their actions, 
and novel approaches to snakebite treatment, NGOs working for human and animal welfare, and 
conservationists interested in reducing human-wildlife conflict. SnakSymp-2017 was inaugurated by Mr. 
Jogu Ramanna, Minister for Forest and Environment, Telangana State. Concurrently with the symposium, 
60+ invited participants took part in a discussion workshop with the objective of reviewing the current 
situation around underpinning research, clinical management, anti-venom manufacturing, epidemiology 
and education/awareness, and to identify an action-oriented plan for mitigation of snakebite.  
 
Dr Anita Malhotra, Dr Wolfgang Wüster (Bangor Uni., UK); Prof. Juan Calvete (Inst. of Biomedicine, Valencia, CSIC, 
Spain); Dr Ulrich Kuch (Inst. of Occupational, Social and Environmental Medicine, Goethe Uni., Germany); Guillermo 
Leon, Francisco Wu Lin, Andres Hernandez (Production Unit, Instituto Clodamiro Picado, Costa Rica); Julien Potet (MSF 
Access Campaign, Geneva, Switzerland); Prof. Dr. M. Abul Faiz (DevCare Foundation, Bangaladesh); Dr. Mohammad 
Abdul Wahed Chowdhury (Dept. of Zoology, Uni. Chittagong, Bangladesh); Prof. Dr. Sanjib Sharma (BP Koraila Institute 
of Health Sciences, Nepal); Achyut Raj Pandey (Nepal Health Research Council, Nepal); Prof Ariaranee Gnanathasan 
(Dept. of Clinical Medicine, Uni. Colombo, Sri Lanka); Prof RPVJ Rajapakse (Dept. of Veterinary Pathobiology, Uni. 
Peradeniya, Sri Lanka); Benjamin Owens (Captive  and Field Herpetology EcoTours, UK).  Dr Karthikeyan Vasudevan, 
Siddharth Bhatia (LaConES, CCMB, Hyderabad); Dr GV Ramana Rao (GVK-Emergency Medicine Research Inst., 
Hyderabad); Dr Robin Doley, Archana Deka, Simran Kaur (Dept. of Molecular Biology and Biotechnology, Tezpur Uni.); 
Dr Tarun Kumar Sharma (Translational Health Science and Technology Inst., Faridabad); Romulus Whitaker, Ajay Kartik 
(Madras Crocodile Bank Trust Centre for Herpetology, Mamallapuram); Gerry Martin (The Gerry Martin Project, 
Bengaluru); Sumanth Madhav (Humane Society International, Bengaluru); Vishal Santra (Simultala Conservationists 
Foundation for Wildlife, Nailkul); Dr Dayal Bandhu Majumdar (Calcutta National Medical College & Hospital); Dr 
Omesh Bharti (Himachal Pradesh State Institute of Health and Family Welfare); Dr Harshdeep Singh Bal (Christian 
Medical College, Vellore); Dr Jaideep Menon (Amrita Institute of Medical Sciences, Kochi); Dr Joseph K Joseph (Little 
Flower Hospital and Research Centre, Angamaly); Dr Sadanand Raut, Dr Pallavi Raut (Vighnahar Nursing Home, Pune); 
Dr Dileep Punde (Punde Hospital, Mukhed); Priyanka Kadam (Snakebite Healing and Education Society, Mumbai); Dr 
MV Khadilkar (Premium Serums and Vaccine Pvt. Ltd., Pune); Jyotsna Singh (MSF India Office, Delhi); Ashish Chauhan, 
Viswanath Hebbi (Indian Inst. of Technology, Delhi); Lois Armstrong, Dr Sharon Cynthia Stephen (Duncan Hospital, 
Raxaul); Karthik N Awathade (Faculty of Life Sciences, JSS Uni., Mysuru); Renu Kadali (VIT Uni., Vellore); Pushpendra 
Singh (Dept. of Biological Science and Engineering, Maulana Azad National Inst. of Technology, Bhopal); Avinash 
Viswanath (Friends of Snakes Soc., Hyderabad); Nishigandha Naik, Amruta Naik (Haffkine Inst. for Training Res. & 
Testing, Mumbai); Ajeeta Longjam, Anurag Bajpai (Manipur Forest Dept.); Teja Chennamsetty (Siddhartha Medical 
College, Guntur); Amudhavalli Singaravelu, Ramani Venkatesan, Praveena Venugopalan (King Inst. of Preventive Med. 
and Res., Chennai); Ajit Nair, P. Vinai Babu, Dhruv Arora, D. Karunkar (VINS Bioproducts Ltd., Hyderabad). 
PARTICIPANTS 
SNAKEBITE MITIGATION AND INNOVATIVE WAYS TO DEVELOP EFFECTIVE ANTI-VENOM 
1-3 DEC 2017, CSIR-CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY, HYDERABAD 
This workshop was organized by Dr Anita Malhotra (Bangor University, UK) and Dr Karthikeyan Vasudevan 
(CCMB, India), who also wrote this brief. The Indian Academy of Sciences (Bengaluru), Indian National 
Science Academy (New Delhi), National Academy of Sciences (Allahabad), BITES project (European Union 
7th Framework Programme, grant no. PIRSES-GA-2013-612131) and Bangor University ESRC Impact 
Acceleration Account (UK) provided financial support.  We thank CSIR for use of facilities and Dr David 




WHY IS SNAKEBITE SUCH A BIG PROBLEM IN INDIA? 
Recent estimates put the number of deaths from snakebite in India at 45,900 per year, the vast majority occurring 
in the rural population1. However, official Government of India figures based on hospital records are c. 30 times 
less than this. Surviving bite victims may be permanently disabled and suffer considerable economic losses2.  
The key to clinical management of snakebites is timely administration of an appropriate anti-venom. However, as 
toxins in snake venoms vary between and within species, the design and production of anti-venom requires 
information on the diversity and distribution of venomous snakes and their toxins, which is not currently available. 
Polyvalent anti-venom (effective against the venom of the “Big 4” species: the common Indian or spectacled cobra, 
the common Indian krait, Russell’s viper and the saw-scaled or carpet viper) is made in India by a number of 
manufacturers. However, major regions of India are occupied by different species, and genetic evidence suggests 
that some of the Big 4 themselves may contain more than one species.  
Venom for manufacture of anti-venom is predominately sourced from one licensed supplier based in Tamil Nadu 
and clinical evidence suggests that the current anti-venom does not neutralize the life-threatening effects of 
snakebite caused by the Big 4 species in other regions due to differences in venom composition. 
The presence of non-immunoglobin (Ig) equine proteins in all commercially available anti-venoms results in a high 
risk of adverse effects such as anaphylactic shock which can kill a patient if not treated promptly. 
Many stakeholders need to be involved to address the problem effectively, including field herpetologists, Forest 
Departments, researchers (genetics, protein biology, epidemiology, health economics, behavioural change), 
clinicians, anti-venom manufacturers, drug regulatory agencies, rural health workers, traditional healers, snake 
rescue organisations, public health authorities, procuring agencies and educators. 
Basic research 
Research on venomous snakes and their venoms 
requires collection of samples of snakes in the wild but 
requires permits from Forest Departments due to their 
protected status in India, a difficult and slow process.  
Other permits, sometimes from different agencies, are 
required for moving venom across State boundaries and 
for foreign researcher/institution involvement.  
Forest Departments can be reluctant to grant permits for 
collection (even when non-lethal protocols are used) as 
substances said to be snake venom and claimed to have 
high economic value are regularly confiscated, 
Multiple applications from different research groups to 
the same states creates tension and wasted effort while 
lack of research funding available to laboratories to 
analyse collected samples delays progress.  
Use of differing methodology, geographical sampling, 
and lack of verification of species involved, reduces the 
value of existing scientific studies on venom variation.   
Short-term: A Global Snakebite Initiative India 
((GSI-I) Research Working Group should be 
formed to co-ordinate collecting effort, establish 
standard methodology for analyses, and agree a 
sample and data sharing protocol. 
GSI-I should work with experts on the Wildlife 
Protection Act (1972) to establish a website for 
researchers outlining the procedures required for 
applying for permits per State. 
Researchers should work with State Forest 
Departments to confirm if venom is present in 
smuggling seizures. If so, establish a database of 
toxins to allow identification of species involved 
and their geographic origin. 
Medium term: A biorepository for snakebite 
research samples should be established at the 
ICAR-National Bureau of Animal Genetic 
Resources, Haryana. 
Longer-term: Govt. of India should simplify 
access to samples from venomous snakes for 
medical research by removing this from the 






Training of doctors, especially junior doctors stationed at 
primary health care (PHC) facilities, is currently 
inadequate and should include basic life-saving 
procedures (e.g., diagnosis and monitoring (including 
proper use of WBCT20 20-minute whole blood clotting 
test3; Rational use of anti-snake venom serum (ASV); 
signs and proper treatment of adverse reactions; 
Intubation and use of artificial ventilation).  
Training modules for PHC doctors are currently only 
taught in West Bengal and Tamil Nadu but could be 
extended to other states in the form of online webinars. 
Diagnostic tests for the identification of biting species is 
not necessary for advancing early treatment with anti-
venom, and will add additional cost to patients.  
Simple clinical algorithms that guide diagnosis of 
systemic envenoming are needed to inform early anti-
venom decision making. Diagnosis need only be 
"envenomed" vs "non-envenomed" when treatment is 
via a polyvalent product. 
There is a marked lack of evidence on which to base 
recommended treatments and robust trials will be 




Currently several AVS manufacturers, largely private 
companies, provide liquid and/or lyophilized product. 
There is wide variation in total protein content, potential 
for adverse reactions, potency, and endotoxin content. 
The cost, quality and consistency of supply of venom 
hampers manufacturers’ ability to improve the product.  
The limited availability of venom from only major 
licensed source also fails to account for geographical 
variation in venom composition. 
The low neutralizing capacity per vial is designed to allow 
flexibility in dosage given the large variation in potential 
venom yields (from milliliters for a large cobra to 
microliters for a saw-scaled viper), but high doses of 
horse proteins are delivered where larger number of 
vials are used.  
The high frequency of adverse reactions experienced is a 
major obstacle to the successful treatment of victims and 
is a consequence of presence of non-Ig horse proteins in 
the final product.   
Short-term: An existing WhatsApp snakebite 
treatment group for telephonic consultation 
exists and should be publicized widely. 
State Governments should supply free ASV in 
government hospitals in all states. 
Medical Council of India should introduce 
compulsory Continuing Medical Education on 
snakebite for doctors’ license renewal. 
Medium term: The Clinical Establishments 
(Registration and Regulation) Act 2010, which 
sets the standards for all health facilities in the 
country, should be reviewed to ensure Level 2 
hospitals are equipped to deal with snakebite 
emergencies.  
Trauma counselling should be included in post-
emergency care provided. 
Registrar General of Births and Deaths should 
make snakebite notifiable using the diagnosis 
code T63.0 (toxic effect of snake venom) and the 
external cause code X20 (contact with venomous 
snakes and lizards). 
MoHFW should revise and improve the National 
Snakebite Treatment Protocol and develop 
simple aids (e.g., flowcharts) for doctors. 
Longer-term: Indian Council for Medical Research 
ACTIONS 
Short-term: Manufacturers should switch from 
bottles to disposable bags for plasma collection 
and include tests for bacterial contamination. 
Medium-term: stablish regional venom collection 
and supply centres (e.g., based on public-private 
partnerships) with strict protocols for snake 
husbandry and venom collection procedures, and 
certification of venom quality. 
Manufacturers should implement strict current 
Good Manufacturing Practice (cGMP) to the 
entire process, with stricter and independent 
Quality Control by the Central Drugs Standard 
Control Organization applied on bulk and final 
product, to reduce incidence of hypersensitivity. 
Longer-term: Pre-clinical and clinical testing of 
products should be mandatory, with Phase IV 





Epidemiology and Public Health 
Many regions of India currently lack snakebite data (e.g., 
northeastern and northern states1, where considerable 
uncertainty about the biting species exists). 
Epidemiological data is particularly urgently needed to 
evaluate the requirement for a different anti-venom in 
these regions. 
The Ministry for Health & Family Welfare (MoHFW), 
through the Integrated Disease Surveillance Programme 
(IDSP) of the National Centre for Disease Control (NCDC), 
should leverage existing district-level health surveillance 
networks to evaluate factors such as gender bias in 
seeking treatment. 
Sample sizes needed for epidemiological studies are 
difficult to achieve but can be increased by including 
significant non-lethal endpoints. 
Antibody-based immuno-assays for identification of 
biting species are limited by within-species venom 
variation in venom and nucleic-acid based alternatives 
(aptamers) could be quickly developed.  
GVK-EMRI, who operate the free 108 ambulance service 
in 16 states and 2 Union Territories, collect data which 
can be leveraged for retrospective and prospective 
epidemiological studies. 
Public Education and Awareness 
 
Prevention of snakebite should be the top priority, and is 
in line with the move from the curative to the 
preventative approach to public health in India4.  
The GSI-I working group should recruit health economists 
and behavioural change experts to investigate 
effectiveness of use of mass and social media to promote 
use of torches at night, sleeping on raised platform with 
use of tucked-in mosquito nets to reduce krait bite risk, 
use of footwear when outdoors, and rodent control on 
reducing numbers of bites. 
School-children should be targeted through the 
curriculum as well as through specific programs as they 
are among the most affected section of society. This 
should include the importance of snakes in the 
ecosystem, what to do if a snake is encountered, 
snakebite as a medical emergency and anti-venom as the 
only cure, discredited and proper methods of first aid, 
awareness of free ambulance service or alternative 
methods for rapid transport to hospital.  
Short-term: State Education Boards should add 
snakebite awareness to existing school curricula. 
GSI-I should provide templates of short videos 
and well-designed posters5 for translation and 
dissemination through State Panchayats and 
community health networks e.g.  Accredited 
Social Health Activists (ASHA). 
GSI-I should provide training material5 for snake 
rescue networks to reduce risk of snakebite. 
Medium-term: GSI-I should lobby state 
Governments which do not yet offer a free 
ambulance service, and review adequacy of 
provision of PHC in rural areas. 
GSI-I should work with traditional healer 
associations to encourage them to direct 
snakebite victims to hospital without delay. 
 
ACTIONS 
Short-term: NCDC should develop simple and 
clear questionnaires for use in hospitals and 
provide assistance to doctors to analyse and 
publish snakebite data. 
GSI-I working group should lobby State Govts. to 
standardize levels of compensation available, 
and align it with compensation for other types of 
human-wildlife conflict. 
MoHFW should review amount available for 
snakebite treatment under the national health 
insurance scheme to ensure it is adequate. 
MoHFW should set up an agency to manage the 
supply chain of ASV in the public sector and 
monitor stocks. 
Medium-term: MoHFW should fund further 
research on social and environmental risk 
factors, and effectiveness of various 
interventions in reducing snakebite. 
Health economists should develop alternative 
more realistic measures of ASV cost-





1 Mohapatra B et al. 2011. Snake bite mortality in India: A nationally 
representative mortality survey. PLoS Negl Trop Dis 5(4):e1018. 2 Vaiyapuri 
et al. 2013. Snakebite and Its Socio-Economic Impact on the Rural 
Population of the Tamil Nadu, India. PLoS ONE 8(11): e80090. 3 World 
Health Organization 2016. Guidelines for the Management of Snake-bites 
2nd Ed. WHO Regional Office for South-East, New Delhi, India. 4 Indian 
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Health Metrics and Evaluation 2017. India: State of the Nations’ States – 
The India State-level Disease Burden Initiative. New Delhi, India.  
 
Further Information and Useful Resources 
 
World Health Organisation factsheet on snakebite envenoming: 
http://www.who.int/mediacentre/factsheets/fs337/en/ 
The Global Snakebite Initiative, an internationally-active non-
profit organisation dedicated to improving access to good 
quality, safe and effective antivenoms in the world’s poorest 
communities: http://www.snakebiteinitiative.org/ 
Report by Health Action International, which conducts research 
and advocacy to advance policies that enable access to 
medicines and for all people: “THEORY OF CHANGE REPORT: 
Preventing and Treating Snakebite in Resource-Poor Settings – 
An Action Plan for Change” available at http://haiweb.org/what-
we-do/global-snakebite-initiative/ 
Bangor University BITES project website: bites.bangor.ac.uk 
Dr Anita Malhotra  
Bangor University, School of Biological Sciences 
3rd Floor, Environment Centre Wales 
Deiniol Road, Bangor LL57 2UW, U.K. 
Email: a.malhotra@bangor.ac.uk 
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Snakebite patient, who died within 20 hrs after receiving 
20 vials of anti-venom. Dr. Shyamal Kundu. 
Funding agencies should ensure that the knowledge gap in underpinning basic research is addressed with a mix 
of short-to-medium term and longer term funding, and should encourage co-operation and standardization of 
approach by targeting funding at consortia of minimum size that involve key stakeholders. 
The Ministry of Environment, Forests and Climate Change (MoEFCC) should work with the Global Snakebite 
Initiative (India) working groups to ensure that adequate amounts of essential samples can be collected in a 
reasonable timeframe. A biorepository for snakebite research samples should be established at the ICAR-
National Bureau of Animal Genetic Resources to reduce the need for repeated collection from the wild. 
The Ministry of Health and Family Welfare (MoHFW) and its associated agencies should improve snakebite 
surveillance by making snakebite a notifiable disease that it reported using the appropriate diagnostic codes. 
Indian Council of Medical Research should fund further research on social and environmental risk factors, 
effectiveness of various interventions in reducing snakebite and true cost-effectiveness of anti-venom. 
The Medical Council of India should require continuing medical education (CME) courses on snakebite to be 
taken as a condition of license renewal, introduce a specific module in basic medical training which includes 
practical life-saving procedures, and provide simple clinical guides for diagnosing envenomation.  
Regional venom collection and supply centres should be established with strict protocols for snake husbandry 
and venom collection procedures, and certification of venom quality. 
Anti-venom manufacturers should implement strict current Good Manufacturing Practice to the entire process, 
with stricter independent quality control by the Central Drugs Standard Control Organization. 
State Education Boards should add snakebite awareness to existing school curricula and posters in local 
languages should be distributed through State Panchayats and community health networks (e.g. ASHA). 
WHAT CAN WE DO NOW? 
CONTACT 
